Alphatec Holdings, Inc. (NASDAQ:ATEC) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have earned a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $17.56.

Several equities analysts recently issued reports on ATEC shares. Needham & Company LLC boosted their price target on Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Barclays boosted their target price on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Alphatec in a report on Tuesday, January 14th.

Insiders Place Their Bets

In other Alphatec news, EVP David Sponsel sold 58,283 shares of the company’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $10.71, for a total transaction of $624,210.93. Following the transaction, the executive vice president now directly owns 502,311 shares in the company, valued at approximately $5,379,750.81. This represents a 10.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 22.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Alphatec

A number of institutional investors and hedge funds have recently modified their holdings of the company. Nisa Investment Advisors LLC boosted its position in Alphatec by 973.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock worth $43,000 after purchasing an additional 4,234 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Alphatec in the 3rd quarter worth about $69,000. Ballentine Partners LLC acquired a new stake in Alphatec in the 4th quarter valued at about $120,000. Net Worth Advisory Group purchased a new position in Alphatec during the 3rd quarter valued at about $76,000. Finally, Mount Yale Investment Advisors LLC acquired a new position in Alphatec during the fourth quarter worth about $152,000. Institutional investors and hedge funds own 66.35% of the company’s stock.

Alphatec Stock Down 2.0 %

ATEC stock opened at $11.38 on Thursday. Alphatec has a 12 month low of $4.88 and a 12 month high of $17.34. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The company has a market cap of $1.61 billion, a price-to-earnings ratio of -8.89 and a beta of 1.41. The company has a fifty day moving average price of $9.80 and a 200 day moving average price of $8.08.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.